Dec/Jan2018

Latest stories

Cleveland Clinic

How Novartis Built a Stronger Brand in MS Therapy

INDUSTRY TRENDS: BY THE NUMBERS

Trending Now

192 Views0 Comments
in Headlines

ICON to acquire PRA Health Sciences

Dublin, Ireland, 24th February 2021- ICON plc, (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, and government and public health organisations, today announced it has entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion, with the per share merger consideration consisting of $80 in cash and 0.4125 shares of ICON stock. The consideration represents an approximately 30% premium to PRA’s closing price as of February 23rd, 2021. More

by hsandm February 24, 2021, 8:39 pm

Read More
899 Views0 Comments
in Headlines

Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

Wilmington, MA , February 17 2021 (Business Wire) — Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million in cash, subject to customary closing adjustments. The transaction is expected to close by the end of the first quarter of 2021, subject to regulatory requirements and customary closing conditions. More

by hsandm February 17, 2021, 7:13 pm

Read More
517 Views0 Comments
in Headlines

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

San Francisco, CA, February 17, 2021 (GLOBE NEWSWIRE) — Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the completion of a $60 million financing. The proceeds will be used to advance Excision’s lead candidate, EBT-101, into a Phase 1/2 clinical trial in patients with chronic HIV infection. The financing will also support preclinical programs including EBT-103 targeting JC Virus for Progressive Multifocal Leukoencephalopathy (PML), EBT-104 for Herpes Simplex Virus, and EBT-107 for Hepatitis B. More

by hsandm February 17, 2021, 6:51 pm

Read More
1 Shares777 Views0 Comments
in Headlines

Henry Schein One Appoints New Chief Executive Officer

American Fork, UT, February 16, 2021 (BUSINESS WIRE) — Henry Schein One, a joint venture of Henry Schein, Inc., and Internet Brands, has announced that Mike Baird will assume the role of Chief Executive Officer, leading all aspects of Henry Schein One’s business. In his new role of CEO, Mr. Baird will lead the organization in driving growth, developing more seamlessly integrated products, and advancing digital innovations that help customers build stronger practices and deliver quality care. More

by hsandm February 16, 2021, 7:37 pm

Read More
1.1k Views0 Comments
in Headlines

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

Duluth, GA., February 16, 2021 (PRNewswire) — Boehringer Ingelheim Animal Health USA Inc. today announced the creation of Pawru, Inc. as a separate Company within the Boehringer Ingelheim Animal Health business. More

by hsandm February 16, 2021, 6:27 pm

Read More
947 Views0 Comments
in Headlines

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

New York NY, February 16 2021 (PRNewswire) — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6,250,000 shares of common stock of the Company at a price to the public of $1.60 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 19, 2021, subject to satisfaction of customary closing conditions. More

by hsandm February 16, 2021, 6:17 pm

Read More

Dec/Jan2018

Latest stories

Cleveland Clinic

How Novartis Built a Stronger Brand in MS Therapy

INDUSTRY TRENDS: BY THE NUMBERS

More stories

HS&M TOP LISTS

What If Digital Could Drive Revenue?

MOTIVIDEOS

Why I Work In Healthcare

She launched Lipitor at Pfizer, and drove $4B at AstraZeneca. What will she do for Mylan?

Great Advice from Great Minds: Success Secrets from Michael Tremblay, President of Astellas Pharma Canada

More Effective Creative for Teva and Syneron

Containing Costs: How We’re All Involved

ICON to acquire PRA Health Sciences

Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

Excision BioTherapeutics Completes $60 Million Financing to Advance CRISPR-Based Infectious Disease Programs

Henry Schein One Appoints New Chief Executive Officer

Boehringer Ingelheim Animal Health USA Establishes Pawru, Inc.

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Latest stories

More stories

Log In

Sign In

Forgot password?

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections